Thus, dysfunctionalities of other DDR factors involved in HR-mediated DSB repair, such as RAD51, ATR, ATM, and CHK1/2, are being studied to expand the spectrum of cancer patients that could benefit from PARP inhibitor treatments [14], [26], [86], [87]. This evidence concerns the gene ATR and cancer.